PURPOSE: The aim of this study was to describe primary non-adherence (PNA) in a Danish general practitioner (GP) setting, i.e. the extent to which patients fail to fill the first prescription for a new drug. We also assessed the length of time between the issuing of a prescription by the GP and the dispensing of the drug by the pharmacist. Lastly, we sought to identify associations between PNA and the characteristics of the patient, the drug and the GP. METHODS: By linking data on issued prescriptions compiled in the Danish General Practice Database with data on redeemed prescriptions contained in the Danish National Prescription Registry, we calculated the rate of PNA among Danish patients from January 2011 through to August 2012. Characteristics associated with PNA were analysed using a mixed effects logistic regression model. RESULTS: A total of 146,959 unique patients were started on 307,678 new treatments during the study period. The overall rate of PNA was 9.3 %, but it varied according to the major groups of the Anatomical Therapeutic Chemical (ATC) Classification System, ranging from 16.9 % for "Blood and bloodforming organs" (ATC group B) to 4.7 % for "Cardiovascular system" (ATC group C). Most of the patients redeemed their prescriptions within the first week. Older age, high income and a diagnosis of chronic obstructive pulmonary disease were found to be significantly associated with lower rates of PNA, while polypharmacy and a diagnosis of ischaemic heart disease were associated with higher rates of PNA. CONCLUSIONS: The overall rate of PNA among Danish residents in a GP setting was 9.3 %. Certain drug classes and patient characteristics were associated with PNA.
PURPOSE: The aim of this study was to describe primary non-adherence (PNA) in a Danish general practitioner (GP) setting, i.e. the extent to which patients fail to fill the first prescription for a new drug. We also assessed the length of time between the issuing of a prescription by the GP and the dispensing of the drug by the pharmacist. Lastly, we sought to identify associations between PNA and the characteristics of the patient, the drug and the GP. METHODS: By linking data on issued prescriptions compiled in the Danish General Practice Database with data on redeemed prescriptions contained in the Danish National Prescription Registry, we calculated the rate of PNA among Danish patients from January 2011 through to August 2012. Characteristics associated with PNA were analysed using a mixed effects logistic regression model. RESULTS: A total of 146,959 unique patients were started on 307,678 new treatments during the study period. The overall rate of PNA was 9.3 %, but it varied according to the major groups of the Anatomical Therapeutic Chemical (ATC) Classification System, ranging from 16.9 % for "Blood and bloodforming organs" (ATC group B) to 4.7 % for "Cardiovascular system" (ATC group C). Most of the patients redeemed their prescriptions within the first week. Older age, high income and a diagnosis of chronic obstructive pulmonary disease were found to be significantly associated with lower rates of PNA, while polypharmacy and a diagnosis of ischaemic heart disease were associated with higher rates of PNA. CONCLUSIONS: The overall rate of PNA among Danish residents in a GP setting was 9.3 %. Certain drug classes and patient characteristics were associated with PNA.
Authors: Michael A Fischer; Niteesh K Choudhry; Gregory Brill; Jerry Avorn; Sebastian Schneeweiss; David Hutchins; Joshua N Liberman; Troyen A Brennan; William H Shrank Journal: Am J Med Date: 2011-11 Impact factor: 4.965
Authors: Henrik Schroll; René Depont Christensen; Janus Laust Thomsen; Morten Andersen; Søren Friborg; Jens Søndergaard Journal: Int J Family Med Date: 2012-07-24
Authors: Maja S Paulsen; Morten Andersen; Janus L Thomsen; Henrik Schroll; Pia V Larsen; Jesper Lykkegaard; Ib A Jacobsen; Mogens L Larsen; Bo Christensen; Jens Sondergaard Journal: J Am Heart Assoc Date: 2012-12-31 Impact factor: 5.501
Authors: Zandra Nymand Ennis; Anne Broe; Anton Pottegård; Thomas P Ahern; Jesper Hallas; Per Damkier Journal: Br J Clin Pharmacol Date: 2018-06-03 Impact factor: 4.335
Authors: Ignacio Aznar-Lou; Ana Fernández; Montserrat Gil-Girbau; Marta Fajó-Pascual; Patricia Moreno-Peral; María Teresa Peñarrubia-María; Antoni Serrano-Blanco; Albert Sánchez-Niubó; María Antonia March-Pujol; Anna Maria Jové; Maria Rubio-Valera Journal: Br J Clin Pharmacol Date: 2017-02-24 Impact factor: 4.335
Authors: Alba Sánchez-Viñas; Carmen Corral-Partearroyo; Montserrat Gil-Girbau; M Teresa Peñarrubia-María; Carmen Gallardo-González; María-Del-Carmen Olmos-Palenzuela; Ignacio Aznar-Lou; Antoni Serrano-Blanco; Maria Rubio-Valera Journal: BMC Prim Care Date: 2022-07-05
Authors: Ignacio Aznar-Lou; Ana Fernández; Montserrat Gil-Girbau; Ramón Sabés-Figuera; Marta Fajó-Pascual; María Teresa Peñarrubia-María; Antoni Serrano-Blanco; Patricia Moreno-Peral; Albert Sánchez-Niubó; Marian March-Pujol; Maria Rubio-Valera Journal: Br J Gen Pract Date: 2017-07-31 Impact factor: 5.386
Authors: Benedicte Lind Barfoed; Dorte Ejg Jarbøl; Maja Skov Paulsen; Palle Mark Christensen; Peder Andreas Halvorsen; Jesper Bo Nielsen; Jens Søndergaard Journal: Int J Family Med Date: 2015-10-08